COMPANY SCIENCE & TECHNOLOGY PIPELINE PARTNERING & LICENSING NEWS & EVENTS CONTACT US NEWS & EVENTS / PRESS RELEASES PRESS RELEASES October 15, 2015 - Exicure Co-Founder Awarded Inaugural Sackler Prize April 22, 2015 - AuraSense Therapeutics Announces Publication of Preclinical Data Demonstrating Immuno-Modulation by its Proprietary Spherical Nucleic Acid Platform February 4, 2015 - AuraSense Therapeutics Adds to Series C Financing October 1, 2014 - AuraSense Therapeutics Expands Leadership Team July 23, 2014 - AuraSense Therapeutics Appoints Biotechnology Veteran David S. Snyder as Chief Financial Officer June 17, 2014 - AuraSense Therapeutics Completes $13.6 Million Series C Equity Investment July 31, 2013 - AuraSense Therapeutics Closes Tranche II of Series B Equity Investment March 2013 - Sergei Gryaznov PhD Joins AuraSense Therapeutics as Chief Technology Officer February 2013 - AuraSense Therapeutics Announces Election of David Walt to Board of Managers December 21, 2011 - AuraSense Therapeutics Secures Series B Equity Investment 8045 Lamon Avenue Suite 410 Skokie, IL 60077 News | Site Map | Privacy & Terms of Use Copyright 2015

COMPANY SCIENCE & TECHNOLOGY PIPELINE PARTNERING & LICENSING NEWS & EVENTS CONTACT US COMPANY / SCIENTIFIC TEAM SCIENTIFIC TEAM Front row, from left: Sergei Gryaznov, PhD; Pinal Patel, PhD; David Giljohann, PhD; Merideth Burkhart, MS; Rishika Agarwal, MS; Shweta Iyer, MS; Blake Tutterow; Scott Mix, MS; Thomas Cayton Middle row, from left: David Snyder, MBA; Weston Daniel, PhD; Gordon Beck, PhD; Aakriti Goel, MS; Samuel Elberts Back row, from left: S. Rao Nallagatla, PhD; Andrew Schook; Sagar Anantatmula, MS; Clayton Rische Not pictured: Richard Kang, PhD; Susan Richards; Elias Papadimas; Bart Anderson, PhD 8045 Lamon Avenue Suite 410 Skokie, IL 60077 News | Site Map | Privacy & Terms of Use Copyright 2015

COMPANY SCIENCE & TECHNOLOGY PIPELINE PARTNERING & LICENSING NEWS & EVENTS CONTACT US CONTACT US / CAREERS CAREERS Exicure is developing a new class of immunomodulatory and gene silencing drugs against validated targets, addressing diseases from inflammatory disorders to oncology. We strive to unlock the potential of nucleic acid therapeutics with our 3-dimensional, spherical nucleic acid (SNA™) constructs. SNA constructs have the potential to overcome one of the most difficult obstacles to nucleic acid therapeutics: safe and effective delivery into cells and tissues. We seek employees who have the passion to help us drive this innovative technology forward to the patients in need and thrive in a fast-paced atmosphere. We are always interested in receiving resumes from highly skilled and experienced candidates. Please send your resume and cover letter to: careers at exicuretx . com. 8045 Lamon Avenue Suite 410 Skokie, IL 60077 News | Site Map | Privacy & Terms of Use Copyright 2015